MedTrace Logo

Experimental Phage Therapy of Bacterial Infections

NCT00945087 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-09-06

No results posted yet for this study

Summary

The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract infections in whom extensive antibiotic therapy failed or the use of the targeted drug is contraindicated.

Conditions

Interventions

OTHER

Bacteriophage preparation

Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.

Sponsors & Collaborators

  • Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences

    lead OTHER

Principal Investigators

  • Andrzej Górski, M.D. Ph.D. · Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945087 on ClinicalTrials.gov